| Bioactivity | DHODH-IN-26 (compound B2) is a mitochondria-targeting DHODH inhibitor. DHODH-IN-26 shows anticancer activity, triggers the formation of reactive oxygen species (ROS), promots mitochondrial lipid peroxidation, and induces ferroptosis[1]. |
| Invitro | DHODH-IN-26 (compound B2) (0.01-100 μM, 72 h) 抑制 4T1、B16F10、U251、GL261、SH-SY5Y、U87 和 A375 细胞的生长[1]。DHODH-IN-26 (50 and 100 nM) 抑制 B16F10 和 A375 细胞集落形成[1]。DHODH-IN-26 (50 and 100 nM, 48 h) 降低 B16F10 和 A375 细胞 PD-L1 蛋白的表达[1] 0 --> DHODH-IN-26 相关抗体: Cell Viability Assay[1] Cell Line: |
| In Vivo | DHODH-IN-26 (compound B2) (腹腔注射，50 mg/kg，连续14天)可抑制C57BL/6 小鼠 B16F10 异种移植模型的肿瘤生长[1]。 MCE has not independently confirmed the accuracy of these methods. They are for reference only. Animal Model: |
| Formula | C44H34BrF2N2O3P |
| Molar Mass | 787.63 |
| Transport | Room temperature in continental US; may vary elsewhere. |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. Hai Y, et al. A novel mitochondria-targeting DHODH inhibitor induces robust ferroptosis and alleviates immune suppression. Pharmacol Res. 2024;202:107115. |